Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 2/20 | 0.41 |
| ▸ | HRAS | P01112 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.38 |
| ▸ | USP4 | Q13107 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.37 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.35 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4860217 | 0.99 | MAPT (0.42) | TOP1HRASESR1ESR2MAPT | |
| SCHEMBL8917157 | 0.91 | HRAS (0.54) | TOP1HRASESR1ESR2MAPT | |
| SCHEMBL7328867 | 0.91 | HRAS (0.54) | TOP1HRASESR1ESR2MAPT | |
| Hydrochloric Acid SCHEMBL6180839 | 0.90 | KDM4E (0.54) | TOP1HRASESR1ESR2MAPT | |
| SCHEMBL4858107 | 0.86 | PKM (0.39) | TOP1HRASESR1ESR2MAPT | |
| SCHEMBL18773492 | 0.82 | TOP1 (0.41) | TOP1HRASESR1ESR2MAPT | |
| SCHEMBL10110891 | 0.79 | SMN1; SMN2 (0.46) | TOP1HRASESR1ESR2MAPT | |
| SCHEMBL25856520 | 0.79 | TOP1 (0.40) | TOP1HRASESR1ESR2MAPT | |
| SCHEMBL26643295 | 0.79 | MAPT (0.36) | TOP1HRASESR1ESR2MAPT | |
| SCHEMBL13682469 | 0.78 | PKM (0.41) | TOP1HRASESR1ESR2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449547-B2 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOPHARMA S.R.L. (IT) | 2008-11-11 | — | — | US | disclosed |
| US-20070060523-A1 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | NAXOSPHARMA S.R.L. (IT) | 2007-03-15 | — | — | US | disclosed |
| EP-1641753-B1 | PROCESS FOR THE SYNTHESIS OF DISTAMYCIN AND DERIVATIVES THEREOF USING 1-METHYL-4-FORMYLAMINO-2-PYRROLECARBONYL CHLORIDE ITERATIVELY AS AN INTERMEDIATE | NAXOSPHARMA S R L (IT) | 2006-10-18 | — | — | EP | disclosed |
| EP-1641753-A1 | PROCESS FOR THE SYNTHESIS OF DISTAMYCIN AND DERIVATIVES THEREOF USING 1-METHYL-4-FORMYLAMINO-2-PYRROLECARBONYL CHLORIDE ITERATIVELY AS AN INTERMEDIATE | Naxospharma S.R.L. (IT) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004106301-A1 | PROCESS FOR THE SYNTHESIS OF DISTAMYCIN AND DERIVATIVES THEREOF USING 1-METHYL-4-FORMYLAMINO-2-PYRROLECARBONYL CHLORIDE ITERATIVELY AS AN INTERMEDIATE | NAXOSPHARMA S.R.L. (IT) | 2004-12-09 | — | — | WO | disclosed |
| EP-0722446-B1 | DISTAMYCIN A ANALOGUES AS ANTITUMOUR OR ANTIVIRAL AGENTS | PHARMACIA ITALIA SPA (IT) | 2002-12-11 | — | — | EP | disclosed |
| US-5753629-A | AMINO ACID DERIVATIVE ANTIBIOTICS; VIRICIDES | PHARMACIA S.P.A. (IT) | 1998-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060523-A1 | Process for the synthesis of distamycin and derivatives thereof using 1-methyl-4-formylamino-2-pyrrolecarbonyl chloride iteratively as an intermediate | DHPS, PCBP1, MRPL21 | TOP1 601/4885HRAS 3606/4885ESR1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.